Microsoft has ended support for its pre-IE11 browsers as of January 2016 and will be discontinuing IE11 support in August 2021.

If you are seeing this message, you are viewing the site on one of these unsupported browsers. We only support the recent versions of major browsers such as Chrome, Firefox, Safari, and Edge.

Thank you.

(click to close and continue using this browser)

Indiana Urologic Association, Inc. (IUA)

Indiana Urologic Association, Inc.

Needs & Objectives

2023 Indiana Urologic Association Annual Meeting
February 25, 2023
Ritz Charles Carmel
Carmel, Indiana

Educational Needs

Urologists, medical oncologist, radiation oncologist, and bladder cancer providers need to be aware of the novel therapeutic options for patients with both localized and metastatic bladder cancer and how these new treatment options have changed the therapeutic landscape and treatment approach.

Opioids are commonly prescribed after ureteroscopy. With an increasing adoption of ureteroscopy for management of urolithiasis, this subset of patients is at high risk for opioid dependence. Urologists should understand how to use multi-modal opiate sparing pain regimens after ureteroscopy.

Legislative policies at both the national and state level deeply impact the modern practice of medicine. Physicians must remain both informed and proactive regarding Health Policy issues that affect them and their patients. Medicare initiatives, the Quality Payment Program, Stark Law Reform, are constantly altering the practice landscape. Urologists must remain informed of these yearly Health Policy changes looming at the state, regional and national levels to provide the best care for their patients.

In order for urologists to document and maximize their reimbursement for services rendered, a thorough and growing understanding of recent changes, along with other updates on coding compliance is necessary.

Though ureteroscopy is commonly performed, unplanned healthcare encounters after surgery occur in approximately 10% of patients and are often due to pain and bothersome lower urinary tract symptoms. Often, these symptoms are attributable to a ureteral stent, which is placed at the conclusion of most ureteroscopy surgeries. Urologists need to be aware of the data supporting stent utilization.

Urologists need to be knowledgeable about the new AUA guidelines for priapism and contemporary techniques for surgical decompression. The AUA Guideline provides a clinical framework for the diagnosis, evaluation, and treatment (non-surgical and surgical) of acute ischemic priapism.

Educational Objectives

At the conclusion of the 2023 IUA Annual Meeting, attendees will be able to:

  1. Discuss the advantages of novel therapeutic options in patients with localized bladder cancer.
  2. Discuss the novel FDA approved therapeutic options in patients with metastatic bladder cancer.
  3. List the options for neoadjuvant/adjuvant therapy in muscle invasive bladder cancer.
  4. Discuss new persistent opiate use as a concept and its risk factors.
  5. Review options for multi-modal pain management after ureteroscopy.
  6. Identify the Health Policy issues facing Urologists in Indiana, the North Central Section region, and nationally.
  7. Explain and implement best practices for coding and billing for the outpatient, inpatient and surgical care of the urologic patient.
  8. Review symptoms commonly associated with stents.
  9. Discuss data and guidelines regarding stent omission.
  10. Describe the definition of uncomplicated ureteroscopy.
  11. Discuss the new AUA guidelines for priapism.
  12. Review contemporary techniques for surgical decompression for priapism.